# BLK-002-I3 conditional authorization gate assessment and review request

Date: 2026-10-26  
Repository: `C:\Users\Flourish\Documents\GitHub\pflow-production claude vs`  
Branch / HEAD: `main` / `d145324be6d5f1c787bceab6baf27ca0ce375eeb`  
Gate disposition: **I2 INDEPENDENT ACCEPTANCE NOT LOCALLY VERIFIABLE — NO NEW I3 IMPLEMENTATION AUTHORIZED BY THIS DIRECTIVE — PLANNING READINESS ONLY**

## 1. Authorization decision

The attached owner directive `PHARMACYFLOW — BLK-002-I3 CONDITIONAL IMPLEMENTATION AUTHORIZATION` makes independent GPT-6 acceptance of BLK-002-I2 a mandatory predecessor. It expressly says that a Sol report or passing tests cannot satisfy the gate and that a missing, inconclusive or unverifiable independent review limits work to read-only inspection, gap documentation, planning and manifest preparation.

The repository contains the Sol-authored I2 design, correction package and historical manifest. It does **not** contain a detailed independent GPT-6 I2 acceptance artifact. Canonical owner records expressly describe PF-SUP-2026-10-26-02 as owner-referenced but locally unavailable/unverified. PF-SUP-2026-10-26-01 is the correction package/checkpoint requesting independent review and expressly says I3 was not yet approved by that checkpoint. Therefore this conditional directive's pre-implementation gate is not independently provable from local evidence.

No source, façade, test or SQL implementation was authored or changed under this conditional directive. Existing I3 files and migrations 000030–000032 were already present in the dirty tree from later separately recorded owner-directed milestones; this assessment neither self-approves nor extends them.

## 2. Repository and preservation findings

- No repository-owned root `AGENTS.md` exists. Only dependency-package instructions under `node_modules/@supabase/*` were found; they do not govern PharmacyFlow source.
- Start/current Git identity for this assessment is `main` at `d145324be6d5f1c787bceab6baf27ca0ce375eeb`.
- Read-only status showed 47 modified and 36 untracked entries before this documentation package. Unrelated work was not reset, cleaned, stashed, staged or overwritten.
- Migrations 000028 and 000029 were inspected only by hash and remain unchanged. No migration or SQL was executed.
- No StoreFlow path or resource was accessed or inspected.

## 3. I2 review snapshot integrity

Historical manifest: `docs/development/BLK002_I2_CORRECTION_MANIFEST_PF-SUP-2026-10-26-01.sha256`.

Current read-only verification result: **6 matching / 6 advanced**.

The six stable review artifacts still match their historical hashes:

| Artifact | Historical/current SHA-256 |
|---|---|
| `scripts/specification/blk002-i2-security-contract.ts` | `24213045f8a50983b58ca4dd192e4aee247c848339374fb0f1a36a6463907bba` |
| `scripts/specification/blk002-i2-security-contract.test.ts` | `509af7666ec0dd5efe2ffe091b36dc0fb5baa4877e1b3b72d090c47a79499d9d` |
| `docs/development/PHARMACYFLOW_BLK002_I2_GATEWAY_PROVIDER_SECURITY_DESIGN_2026-10-26.md` | `9ef876deebf4c75d88526975a84f686286458c6058a8f9c9adcb498713afafd6` |
| `docs/development/PHARMACYFLOW_BLK002_I2_CORRECTION_REVIEW_PACKAGE_PF-SUP-2026-10-26-01.md` | `0c51d098de54f449b68f858ab99abe52807ffe7785a3d71cc58688986480f98e` |
| `supabase/migrations/20261025000028_owner_eligibility_issuer_v1.sql` | `cb9e0ceb134d430e2d7fb8ac3812d3f243eb2660e3e655a3a8608c50a54c4445` |
| `supabase/migrations/20261025000029_owner_eligibility_recovery_v1.sql` | `3973ba51139a4ccfef03aca80e9231b0465738937de0af97f60bd2e425bcfb9e` |

The six mismatches are shared progress/decision/approval/blocker/test/milestone ledgers that advanced after the I2 snapshot. The historical manifest itself remains unchanged. Current ledger content must not be substituted for its historical bytes during review.

## 4. Exact independent-review request

GPT-6 Work should review only the six stable artifacts above, using the historical manifest to confirm their bytes, plus the original owner transcript for I2/ADM-01/REV-01 provenance. The reviewer should explicitly decide whether corrected I2 safely permits the bounded local I3 scope described in section 10 of the correction package.

Required findings:

1. Confirm or reject atomic effect/result/audit semantics in the I2 specification model.
2. Confirm current action-specific authority on execution and recovery, including revoked/rotated actors and applicant-only consumed recovery.
3. Confirm typed fingerprint completeness and rejection of changed commands with unchanged claimed hashes.
4. Confirm stable actor operation identity and immutable canonical results.
5. Review duplicate-ID handling and exact replay.
6. Reconcile proposed lock ordering with unchanged migrations 000028/000029 while stating that sequential tests are not PostgreSQL proof.
7. State whether unresolved provider exact-status recovery and workload-principal authentication are acceptable blockers for **inactive local I3 authoring only**.
8. Give one explicit verdict: `ACCEPTED FOR BOUNDED I3 LOCAL AUTHORING`, `CONDITIONAL WITH ENUMERATED PERMITTED I3 WORK`, or `BLOCKED BY P0/P1`.

No verdict should authorize database/migration execution, grants, principals, credentials, Auth/provider/network/browser/Docker access, signup/manual-admission activation, Git mutation or deployment.

## 5. Planning-ready I3 scope if independently accepted

The smallest permitted plan remains:

1. inactive, non-routed gateway and platform-operator interfaces;
2. abstract workload authentication/current-authority contracts with no credentials or runtime mapping;
3. provider-neutral exact-status interfaces and deterministic fakes only;
4. typed operation identity, exact replay/conflict and conservative uncertain-outcome recovery;
5. pure ADM-01/REV-01 permission and transition models;
6. inspected injected/static/strict-type tests only;
7. a separately reviewed forward-only SQL proposal only if the independent verdict expressly permits SQL authoring—never execution;
8. a scoped manifest and independent review before any I3A/provisioning/integration work.

Existing local I3 artifacts are not reclassified as independently accepted by this plan.

## 6. Current architecture inventory (read-only)

Existing inactive files already model a gateway façade, a separate operator façade, shared canonical identity/current-authority types, provider-neutral injected interfaces, exact recovery and local deterministic tests. Existing migrations 000030–000032 are marked unexecuted and propose roles, operation evidence, durable issuance attempts, authority registries, global operation claims and explicit RPC ACLs. Their presence is source inventory, not evidence that the conditional I2 gate was satisfied or that SQL/provider behavior works.

## 7. Evidence classification

- **Independently verified:** no detailed I2 acceptance artifact available locally.
- **Owner-approved conditionally:** local I3 authoring only after independent I2 acceptance.
- **Locally/Sol reported:** historical I2 and I3 test/type results in repository evidence ledgers.
- **Executed in this assessment:** read-only branch/HEAD/status discovery, instruction discovery, text search and SHA-256 comparison only.
- **Not executed:** injected tests, compiler, SQL/PostgreSQL, RLS/ACL, Auth, provider, network, browser, Docker, services, ports or concurrency acceptance.
- **Owner-deferred:** AUTH-02.
- **Blocked by missing evidence:** this conditional directive's I3 implementation gate.

## 8. Exact files changed by this planning-only assessment

1. `docs/development/PHARMACYFLOW_BLK002_I3_CONDITIONAL_GATE_REVIEW_REQUEST_2026-10-26.md` (new)
2. `docs/mvp/PHARMACYFLOW_OWNER_APPROVALS.md` (conditional-gate reconciliation)
3. `docs/mvp/PHARMACYFLOW_BLOCKER_REGISTER.md` (missing-independent-review blocker)
4. `docs/mvp/PHARMACYFLOW_TEST_EVIDENCE.md` (read-only evidence classification)
5. `docs/mvp/PHARMACYFLOW_MVP_ROADMAP.md` (planning-readiness stop gate)
6. `docs/development/BLK002_I3_CONDITIONAL_GATE_REVIEW_REQUEST_2026-10-26.sha256` (new scoped manifest)

No application, façade, test, migration or protected contract file is in this change list.

## 9. Outstanding approvals and stop condition

Outstanding: the explicit independent I2 verdict requested above. Even a positive verdict permits only the bounded local scope in the owner directive. Provider validation, PostgreSQL/RLS/Auth/concurrency/browser acceptance, identities, credentials, grants, runtime adapters, activation, Git operations and deployment each remain separately prohibited or approval-gated.

Stop at this package and submit it for independent GPT-6 review. Do not begin or continue I3/I3A implementation under this conditional authorization until the missing gate evidence is supplied and checked.

## 10. Safety attestation

No StoreFlow access occurred. No database/migration/SQL, Auth/provider/network, Docker/service/port, credential, browser-storage, installation, privileged grant, Git mutation, activation or deployment operation occurred. Existing dirty/untracked work, migrations, historical manifests, financial/Refund V2/signed-sync/onboarding contracts and production-disabled state were preserved.
